Alphamab Oncology IPO: Valuation Easy to Swallow
Alphamab Co Ltd (9966 HK) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...
535 Views
Henlius (复宏汉霖) Post-IPO Trading: Weak Demands Ahead of Debut, Downside Remains
Shanghai Henlius' IPO was priced at the low end and started trading today. We have highlighted in our earlier note that the IPO is over-valued with...
514 Views
Shanghai Henlius (复宏汉霖) IPO: Take-Aways from Peer PD-1 Sales in China
We have gathered the sales data for PD-1 products from four players in China for the first half of 2019. As its anti-PD-1 monoclonal antibody,...
545 Views
ECM Weekly (14 Sep 2019) - Budweiser APAC, ESR Cayman, Henlius, AllHome, Topsports
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
541 Views
Shanghai Henlius (复宏汉霖) IPO: Newsflow on HLX10 Clinical Trial and ASEAN Commercialization
Shanghai Fosun Pharmaceutical (Group) (2196 HK), the parent company of Shanghai Henlius which in the process of book building today to raise up to...
590 Views